Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Non-invasive ultrasound study reveals causal role of the amygdala in interpreting uncertain emotions.

Areas of the brain activated

Scientists at the University of Oxford have demonstrated, for the first time, that a key emotional centre deep in the human brain directly influences how we interpret ambiguous social cues.

In a new study, published in Neuron, researchers used low-intensity focused ultrasound to temporarily and non-invasively alter activity in the amygdala - a region known to be involved in emotion and affected in depression. They found that this changed how people responded to facial expressions, particularly when those expressions were emotionally unclear.

The findings provide rare causal evidence in humans about how the brain processes uncertainty in emotional situations, with potential implications for understanding mental health conditions.

Miriam Klein-Flügge, Associate Professor and Wellcome Henry Dale and ERC-UKRI Fellow at the Oxford Centre for Integrative Neuroimaging (OxCIN), said: 'It has not been previously possible to change activity in deep areas of the human brain without requiring surgery. Oxford has been a key player in establishing a new, non-invasive neurostimulation technique called transcranial ultrasound stimulation (TUS), over many years, and this is the first study that applies this stimulation to the human amygdala - one of the key centres for emotion processing - while also measuring very precise neuroimaging signals to assess how we have changed the brain.'

Read the full story on the University of Oxford website

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.